CZ286590B6 - Krystalické formy monohydrátu hydrochloridu endo 2,3-dihydro-N-(8-methyl-8-azabicyklo/3,2,1/okt-3 yl)-2-oxo-1H-benzimidazol-1-karboxamidu a monohydrátu hydrochloridu endo-3-ethyl-2,3-dihydro-... - Google Patents

Krystalické formy monohydrátu hydrochloridu endo 2,3-dihydro-N-(8-methyl-8-azabicyklo/3,2,1/okt-3 yl)-2-oxo-1H-benzimidazol-1-karboxamidu a monohydrátu hydrochloridu endo-3-ethyl-2,3-dihydro-... Download PDF

Info

Publication number
CZ286590B6
CZ286590B6 CZ1993443A CZ44393A CZ286590B6 CZ 286590 B6 CZ286590 B6 CZ 286590B6 CZ 1993443 A CZ1993443 A CZ 1993443A CZ 44393 A CZ44393 A CZ 44393A CZ 286590 B6 CZ286590 B6 CZ 286590B6
Authority
CZ
Czechia
Prior art keywords
formula
compound
oxo
azabicyclo
dihydro
Prior art date
Application number
CZ1993443A
Other languages
Czech (cs)
English (en)
Other versions
CZ44393A3 (en
Inventor
Enzo Dr. Cereda
Enrica Dr. Dubini
Antoine Dr. Ezhaya
Grazia Dr. Maffione
Marco Dr. Turconi
Original Assignee
Boehringer Ingelheim Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI920720A external-priority patent/IT1254562B/it
Priority claimed from ITMI920723A external-priority patent/IT1254565B/it
Application filed by Boehringer Ingelheim Italia Spa filed Critical Boehringer Ingelheim Italia Spa
Publication of CZ44393A3 publication Critical patent/CZ44393A3/cs
Publication of CZ286590B6 publication Critical patent/CZ286590B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CZ1993443A 1992-03-26 1993-03-19 Krystalické formy monohydrátu hydrochloridu endo 2,3-dihydro-N-(8-methyl-8-azabicyklo/3,2,1/okt-3 yl)-2-oxo-1H-benzimidazol-1-karboxamidu a monohydrátu hydrochloridu endo-3-ethyl-2,3-dihydro-... CZ286590B6 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI920720A IT1254562B (it) 1992-03-26 1992-03-26 Forma cristallina dell'endo-3-etil-2,3-diidro-n-(8-metil-8-azabiciclo (3.2.1) ott-3-il)- 2-oxo-1h-benzimidazolo-1-carbossamide cloridrato
ITMI920723A IT1254565B (it) 1992-03-26 1992-03-26 Forma cristallina dell'endo-2,3-diidro-n-(8 metil-8-azabiciclo-(3.2.1) ott-3-il)-2-oxo-1h-benzimidazolo-1-carbossamide cloridrato

Publications (2)

Publication Number Publication Date
CZ44393A3 CZ44393A3 (en) 1994-01-19
CZ286590B6 true CZ286590B6 (cs) 2000-05-17

Family

ID=26330860

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ1993443A CZ286590B6 (cs) 1992-03-26 1993-03-19 Krystalické formy monohydrátu hydrochloridu endo 2,3-dihydro-N-(8-methyl-8-azabicyklo/3,2,1/okt-3 yl)-2-oxo-1H-benzimidazol-1-karboxamidu a monohydrátu hydrochloridu endo-3-ethyl-2,3-dihydro-...

Country Status (27)

Country Link
US (1) US5468758A (pl)
EP (1) EP0567767B1 (pl)
JP (1) JP3279707B2 (pl)
AT (1) ATE169016T1 (pl)
AU (1) AU654082B2 (pl)
BR (1) BR1100564A (pl)
CA (1) CA2092510C (pl)
CZ (1) CZ286590B6 (pl)
DE (1) DE69319955T2 (pl)
DK (1) DK0567767T3 (pl)
ES (1) ES2118846T3 (pl)
FI (1) FI113472B (pl)
HR (1) HRP930479B1 (pl)
HU (2) HU211075B (pl)
IL (1) IL105143A (pl)
MX (1) MX9301668A (pl)
NO (1) NO300975B1 (pl)
NZ (1) NZ247234A (pl)
PH (1) PH30413A (pl)
PL (1) PL172890B1 (pl)
RU (1) RU2125054C1 (pl)
SG (1) SG43225A1 (pl)
SI (1) SI9300150B (pl)
SK (1) SK280555B6 (pl)
TW (1) TW385310B (pl)
UA (1) UA37179C2 (pl)
UY (2) UY25938A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2240637T3 (es) 1996-01-17 2005-10-16 Ricoh Company, Ltd. Aparato de fijacion para un aparato de formacion de imagenes.
JPH1039679A (ja) * 1996-05-24 1998-02-13 Ricoh Co Ltd 定着装置
PE20001420A1 (es) 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
US8697722B2 (en) * 2007-11-02 2014-04-15 Sri International Nicotinic acetylcholine receptor modulators
RU2560729C2 (ru) * 2010-01-11 2015-08-20 АСТРАЕА ТЕРАПЕУТИКС, ЭлЭлСи Модуляторы никотиновых ацетилхолиновых рецепторов

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136189A (en) * 1975-09-16 1979-01-23 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. 2-(5-nitro-furfurylidene)-amino-benzimidoles and fungicidal compositions containing the same
IT1231413B (it) * 1987-09-23 1991-12-04 Angeli Inst Spa Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht
US5223511A (en) * 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
GB9121835D0 (en) * 1991-10-15 1991-11-27 Smithkline Beecham Plc Pharmaceuticals
PH31171A (en) * 1992-02-04 1998-03-20 Esai Co Ltd Aminobenzonic acid derivatives useful for treatinggastrointestinal conditions.

Also Published As

Publication number Publication date
MX9301668A (es) 1993-09-01
SK22693A3 (en) 1993-11-10
NO931112D0 (no) 1993-03-25
UA37179C2 (uk) 2001-05-15
JPH0673053A (ja) 1994-03-15
FI113472B (fi) 2004-04-30
JP3279707B2 (ja) 2002-04-30
FI931329L (fi) 1993-09-27
US5468758A (en) 1995-11-21
NZ247234A (en) 1995-12-21
CZ44393A3 (en) 1994-01-19
SK280555B6 (sk) 2000-03-13
AU3541393A (en) 1993-09-30
SI9300150B (sl) 1998-06-30
NO300975B1 (no) 1997-08-25
CA2092510C (en) 2004-02-03
PL172890B1 (pl) 1997-12-31
NO931112L (no) 1993-09-27
CA2092510A1 (en) 1993-09-27
BR1100564A (pt) 2000-06-27
EP0567767A1 (en) 1993-11-03
ES2118846T3 (es) 1998-10-01
HU211131A9 (en) 1995-10-30
HRP930479A2 (en) 1995-02-28
PL298263A1 (en) 1994-01-10
DK0567767T3 (da) 1999-02-01
HUT63846A (en) 1993-10-28
HU211075B (en) 1995-10-30
DE69319955T2 (de) 1999-04-15
SG43225A1 (en) 1997-10-17
TW385310B (en) 2000-03-21
EP0567767B1 (en) 1998-07-29
FI931329A0 (fi) 1993-03-25
ATE169016T1 (de) 1998-08-15
HRP930479B1 (en) 1999-10-31
SI9300150A (en) 1993-09-30
IL105143A (en) 1996-10-16
DE69319955D1 (de) 1998-09-03
UY25939A1 (es) 2001-08-27
PH30413A (en) 1997-05-09
HK1010719A1 (en) 1999-06-25
AU654082B2 (en) 1994-10-20
HU9300868D0 (en) 1993-06-28
RU2125054C1 (ru) 1999-01-20
UY25938A1 (es) 2000-09-29

Similar Documents

Publication Publication Date Title
CN1886408B (zh) 利福昔明的多晶型形式,它们的制备方法及其在药物制剂中的用途
JP2024164208A (ja) Ｂｔｋ阻害剤の結晶形態
CA3255323A1 (en) 5-MEO-DMT CRYSTALLINE HYDROBROMIDE SALT
PT1442023E (pt) Sal de sódio cristalino do telmisartan e sua utilização como antagonista de angiotensina
CZ44393A3 (en) Crystalline forms of endo-2,3-dihydro-n- £8-methyl-8-azabicyclo(3,2,1)oct-3-yl| -2-oxo-1h-benzimidazole-1-carboxamide hydrochloride monohydrate, endo-3-ethyl-2,3-dihydro- ... hydrochloride ammonium hydrate
BG64051B1 (bg) Нова сол
CA2426026A1 (en) Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
WO2011092720A2 (en) Pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts
JP2025503642A (ja) （ｓ）－５－ベンジル－ｎ－（５－メチル－４－オキソ－２，３，４，５－テトラヒドロピリド［３，２－ｂ］［１，４］オキサゼピン－３－イル）－４ｈ－１，２，４－トリアゾール－３－カルボキサミドの結晶性形態
KR100256148B1 (ko) 결정 형태의 엔도-2,3-디하이드로-n-(8-메틸-8-아자비사이클로(3.2.1)옥트-3-일)-2-옥트-1h-벤즈이미다졸-1-카복스아미드 하이드로클로라이드 1수화물 및 엔도-3-에틸-2,3-디하이드로-n-(8-메틸-8-아자비시클로(3.2.1)옥트-3-일)-2옥소-1h-벤즈이미다졸-1-카복스아미드 하이드로클로라이드 1수화물
JP2914324B2 (ja) ピペリジン誘導体の結晶並びにその製造中間体及び製造方法
HK1010719B (en) Crystalline forms of endo-2,3-dihydro-n-(8-methyl-8-azabicyclo (3.2.1)oct-3-yl)-2-oxo-1h-benzimidazole-1-carboxamide hydrochloride monohydrate and of endo-3-ethyl-2,3-dihydro-n-(8-methyl-8-azabicyclo (3.2.1) oct-3-yl)-2-oxo-1 h-benzimidazole-1-carboxamide hydrochloride monohydrate as 5-ht antagonists
CN102225929A (zh) 一种稳定的盐酸法舒地尔水合物化合物
ZA200302520B (en) Crystal forms of 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl] piperazine.hydrochloride.
RU2178789C2 (ru) Новые полиморфные формы дигидрохлорида лесопитрона и их гидратные формы, способы получения и композиции на их основе
CN101119725B (zh) 化学趋化因子受体拮抗剂的固体形式和其使用方法
HK40105022A (en) Crystalline hydrobromide salt of 5-meo-dmt
HK40105022B (en) Crystalline hydrobromide salt of 5-meo-dmt
WO2022263263A1 (en) Crystalline form of avacopan
HK40092799A (zh) Pn6047盐酸盐的多晶型物
BR112020018451B1 (pt) Forma cristalina de tetracloreto de trietilenotetra-amina,composição farmacêutica, método de produção de formas cristalinas de tetracloreto de trietilenotetra-amina e forma cristalina ou composição farmacêutica
CN110950855A (zh) 一种稳定的伊潘立酮化合物

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20120319